#USA #Austin #Rein Therapeutics #LTI-03 #ATS 2025

Rein Therapeutics Showcases Cutting-Edge Research at ATS 2025 Conference

On May 19, 2025, Rein Therapeutics, a clinical-stage biopharmaceutical firm, unveiled significant research developments during the American Thoracic Society (ATS) 2025 International Conference in Austin, Texas. The company presented two crucial posters detailing the potential applications of their innovative product, LTI-03, aimed at treating idiopathic pulmonary fibrosis (IPF).

Key Highlights of the Presented Research

The dual mechanism of LTI-03 was emphasized in the presentations, showcasing its role in promoting the survival of alveolar epithelial cells while simultaneously inhibiting profibrotic signaling pathways. According to Dr. Cory Hogaboam, the Chief Scientific Officer of Rein Therapeutics, these findings bolster their belief in LTI-03's therapeutic capacity, especially in addressing the substantial unmet medical needs in IPF treatment.

Understanding Idiopathic Pulmonary Fibrosis (IPF)

IPF is a debilitating lung disease characterized by progressive scarring of lung tissues, leading to severe functional impairment. It primarily impacts individuals aged 65 and older, often resulting in a grim prognosis within two to five years following diagnosis. With around 100,000 cases reported annually in the U.S., the demand for effective therapies is critical.

Insights from the Posters

The first poster presented research entitled, "Pre-clinical Proof-of-concept of Anti-fibrotic Activity of Caveolin-1 Scaffolding Domain Peptide LTI-03 in Ex Vivo Precision Cut Lung Slices from Patients with Idiopathic Pulmonary Fibrosis." This study assessed the antifibrotic effects of LTI-03 against the current standard treatment, nintedanib, using precision cut lung slices from IPF patients.

Key findings from this research included:

• - Broad attenuation of profibrotic signaling: LTI-03 demonstrated the ability to significantly reduce profibrotic transcripts and proteins in treated lung slices.
• - Induction of AEC1 protective factors: LTI-03 effectively induced the production of soluble receptor for advanced glycation end-products (solRAGE), offering potential health benefits for alveolar epithelial cells.
• - Non-toxic profile: Importantly, LTI-03 did not cause cellular necrosis, a side effect noted with nintedanib, highlighting its potential as a safer therapeutic option.

The second poster focused on the regenerative properties of the Caveolin scaffolding peptides in three-dimensional alveolospheres cultivated from both IPF and normal lung tissue samples.

Further Findings

This study examined the sustainability effects of LTI-03 and LTI-2355 on alveolar epithelial cell type 2 (AEC2) in lung organoid cultures. Key observations included:

• - LTI-03 and LTI-2355 were shown to preserve AEC2 viability within alveolospheres, promoting overall alveolar health.
• - At higher concentrations, LTI-03 increased the size of IPF alveolospheres significantly compared to placebo, marking a promising avenue for future research.
• - Conversely, nintedanib exhibited growth-inhibiting effects on normal lung organoids, further emphasizing the potential of LTI-03 as a therapeutic alternative.

Looking Ahead

Rein Therapeutics is not only optimistic about the implications of these findings but is currently in the early stages of its Phase 2 RENEW trial evaluating the safety, tolerability, and effectiveness of LTI-03 in IPF patients. The interim data from this trial is expected to be released within the first half of the upcoming year.

The ongoing commitment of Rein Therapeutics to developing innovative solutions for conditions like IPF stands as a beacon of hope for countless patients seeking new treatment options. As research continues and clinical trials progress, the therapeutic landscape for IPF may see much-needed advancements in the near future.

About Rein Therapeutics

Rein Therapeutics focuses on developing first-in-class therapies for significant unmet medical requirements, especially in pulmonary and fibrosis disorders. Their lead candidate, LTI-03, is advancing through clinical trials, signifying Rein’s dedication to transforming the treatment approach for debilitating conditions such as IPF.